Tamoxifen

Talaeı, Ali; Pourgholami, Mohammad H.; Khatibi-Moghadam, Hoda; Farıdhosseını, Farhad; Farhoudi, Fateme; Askari-Noghani, Arash; Sadeghi, Ramin

doi:10.1097/jcp.0000000000000492

Cited by 31 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, TMX has also been reported to be an effective antimanic treatment in pediatric population [80]. In a recent meta-analysis, TMX was found to be effective as monotherapy and as an adjunctive treatment for manic symptoms [13]. Recently, monotherapy with endoxifen, a metabolite of TMX and a potent PKC inhibitor [81], was found to be as effective as with valproic acid (extended release 1,000 mg/day) in mitigation of manic symptoms [82].…”

Section: Pkc Translocation and Activitymentioning

confidence: 99%

“…Our advances in neuroimaging techniques, such as in vivo magnetic resonance imaging, and novel genetic approach, such as convergent functional genomics, are providing us endophenotypic characteristics of BD [11]. After 3 decades of intensive preclinical and translational research, protein kinase C (PKC) has come to be recognized to play a central role in the pathophysiology of BD [12,13,14]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

et al. 2017

View full text Add to dashboard Cite

Bipolar disorder (BD) is a major health problem. It causes significant morbidity and imposes a burden on the society. Available treatments help a substantial proportion of patients but are not beneficial for an estimated 40-50%. Thus, there is a great need to further our understanding the pathophysiology of BD to identify new therapeutic avenues. The preponderance of evidence pointed towards a role of protein kinase C (PKC) in BD. We reviewed the literature pertinent to the role of PKC in BD. We present recent advances from preclinical and clinical studies that further support the role of PKC. Moreover, we discuss the role of PKC on synaptogenesis and neuroplasticity in the context of BD. The recent development of animal models of BD, such as stimulant-treated and paradoxical sleep deprivation, and the ability to intervene pharmacologically provide further insights into the involvement of PKC in BD. In addition, the effect of PKC inhibitors, such as tamoxifen, in the resolution of manic symptoms in patients with BD further points in that direction. Furthermore, a wide variety of growth factors influence neurotransmission through several molecular pathways that involve downstream effects of PKC. Our current understanding identifies the PKC pathway as a potential therapeutic avenue for BD.

show abstract

Section: Pkc Translocation and Activitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Tamoxifen is downgraded because of the risk of uterine cancer and the lack of clinical experience despite evidence for efficacy. Combination treatments with carbamazepine or oxcarbazepine (level 3),163 haloperidol (level 2),144, 164 or tamoxifen (level 2)165 plus lithium or divalproex are also included as third‐line. Repetitive transcranial magnetic stimulation (rTMS) in the right prefrontal cortex at 110% motor threshold (level 3)166 can also be considered in combination with pharmacotherapy.…”

Section: Acute Management Of Bipolar Maniamentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…Three additional trials have been carried out to test the effectiveness of tamoxifen either as an adjunct- or mono- therapy. A meta-analysis of these three trials as well as the two described above observed that tamoxifen is an effective treatment for bipolar mania in both males and females, but that further studies utilizing a larger sample size and a longer follow up duration will be necessary to make any conclusions as to its safety and efficacy (Talaei et al, 2016). It is also worth noting that in one trial, the efficacy of tamoxifen in treating bipolar mania was specific and not mimicked by the antiestrogen medroxyprogesterone which does not inhibit PKC (Kulkarni et al, 2006).…”

Section: Therapeutic Utility Of Tamoxifen In Inhibiting Maniamentioning

confidence: 99%

Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Mikelman

Mardirossian

Gnegy

2017

Journal of Chemical Neuroanatomy

View full text Add to dashboard Cite

Although best known as a selective estrogen receptor modulator (SERM), tamoxifen is a drug with a wide range of activities. Tamoxifen has demonstrated some efficacy has a therapeutic for bipolar mania and is believed to exert these effects through inhibition of protein kinase C (PKC). As the symptoms of amphetamine treatment in rodents are believed to mimic the symptoms of a manic episode, many of the preclinical studies for this indication have demonstrated that tamoxifen inhibits amphetamine action. The amphetamine-induced increase in extracellular dopamine which gives rise to the ‘manic’ effects is due to interaction of amphetamine with the dopamine transporter. We and others have demonstrated that PKC reduces amphetamine-induced reverse transport through the dopamine transporter. In this review, we will outline the actions of tamoxifen as a SERM and further detail another known action of tamoxifen—inhibition of PKC. We will summarize the literature showing how tamoxifen affects amphetamine action. Finally, we will present our hypothesis that tamoxifen, or an analog, could be used therapeutically to reduce amphetamine abuse in addition to treating mania.

show abstract

Tamoxifen

Abstract: Tamoxifen can be considered an effective treatment for manic bipolar patients. Making a conclusion regarding the efficacy and safety for longer periods warrants further studies with a larger sample size and longer follow-up duration.

Cited by 31 publications

References 16 publications

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Contact Info

Product

Resources

About